
Venture capital · Early stage
AllerFund
AllerFund is a mission-driven, for-profit venture capital firm focused solely on the food allergy community. It backs early-stage companies developing therapies, diagnostics, devices and products for people with food allergies.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is AllerFund right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (SEC adviser filings). Values are the gross assets each filing reports, not fund sizes.
Latest investments
Rounds AllerFund joined, from press and the firm’s own posts.
Every round AllerFund joined
Round sizes, AllerFund’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company AllerFund backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet AllerFund
Events where AllerFund’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
AllerFund is based in New York, United States.
3 fund vehicles are on public registers (SEC adviser filings), including ALLERFUND I, L.P., ALLERFUND YUMI SPV2, LLC and ALLERFUND YUMI SPV, LLC.
Stages: Early stage. Sectors: Impact. From the firm’s own website.
The firm aims to create new therapies and products that improve life for people with food allergies. It screens deals like other venture funds but weighs clinical and community impact more heavily. It works with scientists and entrepreneurs to build businesses from promising research, offering business advice and support. From the firm’s own website.
AllerFund lists 8 portfolio companies on its website, including anojai, Atanis Biotech, evoendo, IgGenix and Latitude.
Firms whose websites list some of the same companies include Allumia Ventures, FemHealth Ventures and Good Friends.
Know before AllerFund’s next round is announced.
PRO tracks AllerFund’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.